Search ↗

Comparison

Adipotide vs Semaglutide

Adipotide is fat loss; Semaglutide is GLP-1 & incretins. They are compared here because they are frequently considered against each other, not because they act alike.

On published evidence alone, Semaglutide is the better documented of the two (regulator approved). That is a statement about the state of the literature, not a recommendation.

Adipotide Semaglutide
Class Fat loss GLP-1 & incretins
Evidence Animal models only Regulator approved
Human trials ~1 ~90
Half-life ~30-60 minutes ~7 days
Reported range 500 mcg - 1 mg 250 mcg - 2.4 mg
Frequency Research protocols only Once weekly, titrated over 16+ weeks
Routes Subcutaneous Subcutaneous, Oral
FDA approved No Yes
Research use only Yes No
Banned in sport No No
Studied for Obesity research Type 2 diabetes, Chronic weight management, Cardiovascular risk reduction
Reported side effects Kidney tubule changes (primate data), Dehydration, Injection-site reactions, Reduced appetite Nausea, Vomiting, Diarrhoea, Constipation, Abdominal pain, Injection-site reactions

Adipotide

Adipotide is a chimeric peptide combining a prohibitin-targeting homing sequence with a proapoptotic domain. It binds prohibitin on the endothelial cells of white adipose tissue vasculature and triggers apoptosis, effectively starving fat depots of blood supply rather than acting on metabolism. A 2011 study in obese rhesus monkeys showed substantial weight and fat loss, along with dose-dependent kidney tubule changes that the authors described as predictable and reversible. It has not become an approved medicine. This is not a compound with a favourable risk profile and the page should say so unambiguously.

Semaglutide

Semaglutide is a GLP-1 analog with roughly 94% homology to native GLP-1, modified by substituting alpha-aminoisobutyric acid at position 8 to resist DPP-4 cleavage and by attaching a C18 fatty diacid chain that binds albumin. Together these give a half-life of about a week, allowing once-weekly dosing. It lowers blood glucose through glucose-dependent insulin secretion and glucagon suppression, slows gastric emptying, and acts on hypothalamic appetite centres to reduce energy intake. The STEP trial programme reported mean weight reductions near 15% of body weight at 68 weeks on 2.4 mg weekly.

Adipotide vs Semaglutide: common questions

What is the difference between Adipotide and Semaglutide?

Adipotide is fat loss and Semaglutide is GLP-1 & incretins, so they act on different pathways. Adipotide: A proapoptotic peptide that destroys the blood supply to fat tissue. Caused kidney tubule changes in a primate study. Semaglutide: A long-acting GLP-1 receptor agonist and the compound that reset expectations for pharmacological weight loss.

Which has stronger evidence, Adipotide or Semaglutide?

Semaglutide has the stronger evidence base (regulator approved, about 90 human studies) compared with Adipotide (animal models only).

Are Adipotide and Semaglutide FDA approved?

Only Semaglutide is FDA approved (Type 2 diabetes mellitus (Ozempic, Rybelsus); Chronic weight management (Wegovy); Cardiovascular risk reduction in established CVD with overweight or obesity; Reducing the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (Ozempic, January 2025); Noncirrhotic MASH with moderate to advanced liver fibrosis in adults (Wegovy, accelerated approval August 2025)). Adipotide is not approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 163360068) ↗ · structure, identifiers, synonyms
  2. FDA: Unapproved drugs and "research use only" products ↗ · regulatory status of non-approved products
  3. PubChem compound record (CID 56843331) ↗ · structure, identifiers, synonyms
  4. DailyMed: FDA-approved labeling for Semaglutide ↗ · indications, dosing, warnings as approved
  5. FDA Drugs@FDA database ↗ · approval history
  6. CAS Registry Number 910463-68-2 ↗ · chemical identity

Published literature

  1. Bora B, Das N, Bera A, et al.. Fluorinated High-Valent Sn(IV) Porphyrins Show Remarkable Photodynamic Activity in Cancer Cells.ChemMedChem 2024.PubMed 39017962 · doi:10.1002/cmdc.202400376
  2. Hu PL, Lin JS, Meng H, et al.. A novel "three-dimensional-printed individual guide template-assisted percutaneous vertebroplasty" for osteoporotic vertebral compression fracture: a prospective, controlled study.J Orthop Surg Res 2021.PubMed 34016139 · doi:10.1186/s13018-021-02471-w
  3. McGurgan PM, Olson-White D, Holgate M, et al.. Fitness-to-practise policies in Australian medical schools--are they fit for purpose?.Med J Aust 2010.PubMed 21143055 · doi:10.5694/j.1326-5377.2010.tb04098.x
  4. El-Etreby NM, Ghazy AA, Rashad R. Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-β pathways.J Ovarian Res 2017.PubMed 28427435 · doi:10.1186/s13048-017-0325-4
  5. Barnhart KF, Christianson DR, Hanley PW, et al.. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.Sci Transl Med 2011.PubMed 22072637 · doi:10.1126/scitranslmed.3002621
  6. Bora B, Das N, Sultana JP, et al.. Mn(III) porphyrins as photosensitizers: structural, photophysical and anticancer studies.Dalton Trans 2025.PubMed 40673971 · doi:10.1039/d4dt03432e
  7. Criscione L. Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys".Sci Transl Med 2012.PubMed 22539771 · doi:10.1126/scitranslmed.3003760
  8. Laut KG, Foldspang A. The effects on length of stay of introducing a fast track patient pathway for myocardial infarction: a before and after evaluation.Health Serv Manage Res 2012.PubMed 22323669 · doi:10.1258/hsmr.2011.011021
  9. Wilding JPH, Batterham RL, Davies M, et al.. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Diabetes Obes Metab 2022.PubMed 35441470 · doi:10.1111/dom.14725
  10. Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA 2022.PubMed 35015037 · doi:10.1001/jama.2021.23619
  11. Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity.N Engl J Med 2021.PubMed 33567185 · doi:10.1056/NEJMoa2032183
  12. Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.JAMA 2021.PubMed 33755728 · doi:10.1001/jama.2021.3224
  13. Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.N Engl J Med 2025.PubMed 40353578 · doi:10.1056/NEJMoa2416394
  14. Wharton S, Freitas P, Hjelmesæth J, et al.. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.Lancet Diabetes Endocrinol 2025.PubMed 40961952 · doi:10.1016/S2213-8587(25)00226-8
  15. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.N Engl J Med 2023.PubMed 37952131 · doi:10.1056/NEJMoa2307563
  16. Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med 2021.PubMed 34170647 · doi:10.1056/NEJMoa2107519

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.